Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.

Background: The antibody-drug conjugate sacituzumab govitecan (SG) prolongs progression-free survival and overall survival in patients with refractory/relapsed metastatic triple-negative breast cancer (mTNBC). Here, we investigated its effect on health-related quality of life (HRQoL).

Methods: This analysis was based on the open-label phase III ASCENT trial (NCT02574455).

Imaging of the nontraumatic acute abdomen.

Plain-film radiography of the abdomen is often the first-line imaging modality used for the patient in the ED. It is capable of demonstrating abnormal locations of gas, abnormal viscera, calcifications and foreign material, and skeletal and lower lung pathology. PFR findings may aid in the decision to proceed to other modalities.

Written informed consent for i.v. contrast-enhanced radiography: patients' attitudes and common limitations.

In a multiinstitutional study, we surveyed 902 patients who were undergoing IV contrast-enhanced CT or IV urography; the purpose of the study was to determine patients' reactions to being given a written description of some of the risks associated with radiographic contrast material just before undergoing the examination. Ninety percent of the patients who responded said they would rather receive this information than not receive it. Ten percent said they preferred not to be given the information.

Intrarenal pheochromocytoma: preoperative angiographic diagnosis.

This report documents the angiographic, urographic, and tomographic findings in a patients with a pheochromocytoma within the renal capsule and separate from a normal adrenal gland.